Hormonal, Metabolic, and Signaling Interactions in PAH
Recruiting · NCT01884051 · Observational (researchers observe without assigning treatment) · Lead sponsor: Vanderbilt University Medical Center
View the official record on ClinicalTrials.gov →What this trial is about
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
Who can take part
Age range
Up to 90 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Project 1
- Inclusion:
- Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons
- Age 0-90, age 12-90 for skin biopsy
- Exclusion:
- Other diagnosis
- Age greater than 90, age less than 12 or greater than 90 for skin biopsy
- Project 2
- Inclusion:
- Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
- 0-90
- Subjects with reasonably easy access to clinic for blood collection and other testing
- Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing
- Exclusion:
- Other diagnosis
- 0-90
- Subjects with difficulty reaching clinic for blood collection and other testing
- Subjects unable to tolerate fasting state
- Project 3
- Inclusion:
- Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
- 7-90
- Exclusion:
- Other diagnosis
- Age less than 7 or greater than 90
Where it is running
1 location listed across 1 US state.
- Vanderbilt University Medical Center - Nashville, Tennessee, United States